Dear Editors, Recently, Lee et al. reported seven dogs with glycogen storage disease (GSD) type Ia treated with adenoassociated virus (AAV) vector-mediated gene therapy that apparently prevented long-term hepatic or renal complications (Lee et al. 2018) . However, there are problems with this conclusion. Notably, Lee et al. describe how dogs underwent 24-h care, receiving glucose feeds every 30-60 min. Furthermore, Lee et al. describe two GSD Ia dogs on this same rigorous dietary therapy that lived to > 5 years of age with mostly normal laboratory values, implying that gene therapy had few additional benefits over nutritional therapy.
Our group recently published a very similar gene therapy study, but the GSD Ia dogs were maintained on a more typical diet of only three feedings per day (Brooks et al. 2018 ). However, 4/5 AAV vector-treated dogs developed hepatocellular adenomas and carcinoma and 3/5 developed chronic kidney disease. The key difference between the two studies was the degree of nutritional support and not the gene therapy. Both studies demonstrated low hepatic glucose 6-phosphatase (G6Pase) activity in dogs at the endpoint, as well as marked hepatic glycogen accumulation. Fig. 2 ; dog GE) in association with low G6Pase activity (Fig. 3 ). In contrast, Brooks et al. reported higher vector DNA (0.04-0.16 copies/cell; Supplementary Fig. 2 ) and G6Pase activity (28% of carrier activity; Fig. 1 ) in the liver. Thus, the effect of gene therapy was similar in both studies.
Lee et al. reported no renal complications, other than proteinuria in one dog and mild, intermittent increases in bloody urea nitrogen (BUN) and/or creatinine in two different dogs. Importantly, recombinant AAV8 vectors highly like the one used by Lee et al. had In conclusion, both papers demonstrate that gene therapy has greatly prolonged life in GSD Ia dogs and led to low levels of G6Pase activity persistence. However, evidence is lacking that gene therapy in the absence of a strict dietary regimen can prevent hepatocellular tumors and renal disease.
Communicating Editor: Terry Derks
